Clinical Trial Update: Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on steady-state trough concentrations, safety, and immunogenicity of subcutaneous abatacept in rheumatoid arthritis patients …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ORENCIA (ABATACEPT)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-04-08